Classification and Prognostic Evaluation of Left Ventricular Remodeling in Patients With Asymptomatic Heart Failure

Pugliese, Nicola Riccardo; Fabiani, Iacopo; Carrubba, Salvatore La; Conte, Lucia; Antonini‐Canterin, Francesco; Colonna, Paolo; Caso, Pio; Benedetto, Frank; Santini, Veronica; Carerj, Scipione; Romano, Maria Francesca; Citro, Rodolfo; Bello, Vitantonio Di

doi:10.1016/j.amjcard.2016.09.018

Cited by 27 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was recently shown that this 8‐group classification is superior to the classic 4 groups for prognostic stratification in patients with heart failure stage A and B …”

Section: Discussionsupporting

confidence: 86%

New classification of geometric ventricular patterns in severe aortic stenosis: Could it be clinically useful?

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was recently shown that this 8‐group classification is superior to the classic 4 groups for prognostic stratification in patients with heart failure stage A and B …”

Section: Discussionsupporting

confidence: 86%

New classification of geometric ventricular patterns in severe aortic stenosis: Could it be clinically useful?

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 Accordingly, recent echocardiographic studies have related the 4group classification of LVH system to clinical outcomes in patients with hypertension, 17 coronary artery disease, 18 asymptomatic heart failure, 22 and in the general population with normal LV systolic function and no history of heart failure. 21 Accordingly, recent echocardiographic studies have related the 4group classification of LVH system to clinical outcomes in patients with hypertension, 17 coronary artery disease, 18 asymptomatic heart failure, 22 and in the general population with normal LV systolic function and no history of heart failure.…”

Section: Discussionmentioning

confidence: 99%

Refined 4‐group classification of left ventricular hypertrophy based on ventricular concentricity and volume dilatation outlines distinct noninvasive hemodynamic profiles in a large contemporary echocardiographic population

Barbieri¹,

Rossi

Gaibazzi

et al. 2018

Echocardiography

View full text Add to dashboard Cite

show abstract

“…Remodeling restores the contour of the chamber by removing poorly functioning areas to improve its efficiency . Classification of such states can be achieved by evaluating LV mass, LV volume, the ratio of LV mass/volume (M/V), and relative LV wall thickness (RWT) . Thus, the spectrum of LV geometric adaptation can be measured using these geometric parameters.…”

Section: Caveats Challenges and Insights On The Diagnosis And Theramentioning

confidence: 99%

“…Thus, the spectrum of LV geometric adaptation can be measured using these geometric parameters. Ventricular hypertrophy (VH) is classified as concentric when the RWT is increased, while VH is classified as eccentric when the RWT is not increased; a third pattern, termed concentric remodeling, occurs when RWT but not ventricular mass is increased . Analysis of cardiac function is the major focus of echocardiography, and measuring LVEF has been the clinical standard; however, LVEF has shown its limitations for early detection of myocardial dysfunction .…”

Section: Caveats Challenges and Insights On The Diagnosis And Theramentioning

confidence: 99%

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng

Kros

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune‐based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T‐cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients. Cardiac complications represent unresolved and potentially life‐threatening conditions in cancer survivors, while effective clinical management remains quite challenging. As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer‐related survival, regardless of the oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges and pinpointing real‐time insights in general terms under the context of clinical cardiotoxicity induced by the fourth and fifth modalities of cancer treatment. The information ranges from basic science to clinical management in the field of cardio‐oncology and crosses the interface between oncology and onco‐pharmacology. The complexity of the ongoing clinical problem is addressed at different levels. A better understanding of these research‐practice gaps may advance research initiatives on the development of mechanism‐based diagnoses and treatments for the effective clinical management of cardiotoxicity.

show abstract

Classification and Prognostic Evaluation of Left Ventricular Remodeling in Patients With Asymptomatic Heart Failure

Cited by 27 publications

References 27 publications

New classification of geometric ventricular patterns in severe aortic stenosis: Could it be clinically useful?

New classification of geometric ventricular patterns in severe aortic stenosis: Could it be clinically useful?

Refined 4‐group classification of left ventricular hypertrophy based on ventricular concentricity and volume dilatation outlines distinct noninvasive hemodynamic profiles in a large contemporary echocardiographic population

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Contact Info

Product

Resources

About